Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: A self-controlled case series analysis - PubMed (original) (raw)

Observational Study

Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: A self-controlled case series analysis

Sherrie L Aspinall et al. Pharmacol Res Perspect. 2020 Dec.

Abstract

The objective of this study was to evaluate the association between fluoroquinolone (FQ) use and the occurrence of aortic aneurysm/dissection (AA/AD), acute myocardial infarction (AMI), ventricular arrhythmias (VenA), and all-cause mortality vs other commonly used antibiotics. We conducted a self-controlled case series analysis of patients who experienced the outcomes of AA/AD, AMI, and VenA, based on diagnosis codes from emergency department visits and hospitalizations within Veterans Health Administration, and death in FY2014-FY2018. These Veterans also received outpatient prescriptions for FQs. Conditional Poisson regression models were used to estimate the association between FQs and each of the outcomes vs antibiotics of interest (ie amoxicillin or amoxicillin/clavulanate, azithromycin, doxycycline, cefuroxime or cephalexin, or sulfamethoxazole-trimethoprim), adjusted for time-varying covariates. Using a 30-day risk period after each antibiotic prescription, adjusted incidence rate ratios (aIRRs) for FQs vs each comparator antibiotic were not statistically different for outcomes of VenA or AMI. For AA/AD, incidence was higher during FQ risk periods vs amoxicillin [aIRR 1.50 (95% CI 1.01, 2.25)] and azithromycin [aIRR 2.15 (95% CI 1.27, 3.64)] risk periods. A significantly increased risk of mortality was observed with FQs vs each antibiotic of interest. FQs were associated with an increased risk of AA/AD vs amoxicillin and azithromycin and an increased risk of all-cause mortality vs multiple antibiotics commonly used for outpatient infections. Although the differences in event rates are small, FQ use should be limited to serious infections without appropriate alternatives.

Keywords: Veterans; adverse drug reactions; fluoroquinolones.

Published 2020. This article is a U.S. Government work and is in the public domain in the USA. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest.

Figures

FIGURE 1

FIGURE 1

Sample construction

FIGURE 2

FIGURE 2

Example antibiotic risk and non‐risk periods for outcomes

Similar articles

Cited by

References

    1. Suzuki H, Perencevich EN, Alexander B, et al. Inpatient fluoroquinolone stewardship improves the quantity and quality of fluoroquinolone‐prescribing at hospital discharge: a retrospective analysis among 122 Veterans Health Administration Hospitals. Clin Infect Dis. 2019;71(5):1232‐1239. - PubMed
    1. Kelly AA, Jones MM, Echevarria KL, et al. A report of the efforts of the veterans health administration national antimicrobial stewardship initiative. Infect Control Hosp Epidemiol. 2017;38(5):513‐520. - PubMed
    1. [No authors listed] In brief: more fluoroquinolone warnings. Med Lett Drugs Ther. 2018;60(1553):136. - PubMed
    1. FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 12–20‐2018. https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐warns‐about‐i... (accessed December 16, 2019)
    1. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources